J
Jiao Wu
Researcher at Fourth Military Medical University
Publications - 21
Citations - 1281
Jiao Wu is an academic researcher from Fourth Military Medical University. The author has contributed to research in topics: Signal transduction & Integrin. The author has an hindex of 12, co-authored 21 publications receiving 654 citations.
Papers
More filters
Journal ArticleDOI
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.
Ke Wang,Wei Chen,Zheng Zhang,Yong-Qiang Deng,Jian-Qi Lian,Peng Du,Ding Wei,Yang Zhang,Xiu-Xuan Sun,Li Gong,Xu Yang,Lei He,Lei Zhang,Zhiwei Yang,Jie-Jie Geng,Ruo Chen,Zhang Hai,Bin Wang,Yu-Meng Zhu,Gang Nan,Jian-Li Jiang,Ling Li,Jiao Wu,Peng Lin,Wan Huang,Liangzhi Xie,Zhaohui Zheng,Kui Zhang,Jinlin Miao,Hong-Yong Cui,Min Huang,Jun Zhang,Ling Fu,Xiang-Min Yang,Zhongpeng Zhao,Shihui Sun,Hongjing Gu,Zhe Wang,Chun-Fu Wang,Yacheng Lu,Liu Yingying,Qing-Yi Wang,Huijie Bian,Ping Zhu,Zhi-Nan Chen +44 more
TL;DR: A novel virus entry route, CD147-spike protein, is revealed, which provides an important target for developing specific and effective drug against COVID-19.
Journal ArticleDOI
Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress
Meng Lu,Jiao Wu,Zhi-Wei Hao,Yu-Kui Shang,Yu-Kui Shang,Jing Xu,Gang Nan,Xia Li,Zhi-Nan Chen,Huijie Bian +9 more
TL;DR: The ectopic CD147‐polarized distribution on basolateral membrane promotes hepatocyte depolarization by activation of the CD147–integrin α5β1–E‐cadherin ubiquitination–partitioning defective 3 decrease and β‐catenin translocation signaling cascade, replenishing a molecular pathway in hepatic carcinogenesis.
Journal ArticleDOI
Extracellular Membrane-proximal Domain of HAb18G/CD147 Binds to Metal Ion-dependent Adhesion Site (MIDAS) Motif of Integrin β1 to Modulate Malignant Properties of Hepatoma Cells
TL;DR: The results indicate that the interaction of HAb18G/CD147 extracellular I-type domain with the integrin β1 metal ion-dependent adhesion site motif activates the downstream FAK signaling pathway, subsequently enhancing the malignant properties of HCC cells.
Journal ArticleDOI
Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation
Huijie Bian,Jia-Sheng Zheng,Gang Nan,Rui Li,Changsheng Chen,Cai-Xia Hu,Yang Zhang,Bin Sun,Xi-Long Wang,Shi-Chang Cui,Jiao Wu,Jing Xu,Ding Wei,Xiao-Yong Zhang,Hai-Chun Liu,Wuwei Yang,Yong Ding,Jing Li,Zhi-Nan Chen +18 more
TL;DR: The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuxIMab target (ie, CD147)-positive subpopulation (P = .007) and may yield prevention of tumor recurrence after RFA.
Journal ArticleDOI
HAb18G/CD147 promotes radioresistance in hepatocellular carcinoma cells: a potential role for integrin β1 signaling
TL;DR: Evidence is provided for CD147 as an important determinant of radioresistance via the regulation of integrin β1 signaling and forhibition of the HAb18G/CD147 integrin interaction to improve the efficiency of radiosensitivity and provide a potential new approach for HCC therapy.